Since PPAR-α and PPAR-γ agonists can improve insulin resistance, liver steatosis, oxidative stress, inflammation, adipocytokines secretion, and fibrosis, saroglitazar as a dual PPAR-α/γ agonist, seems to be a rational choice in this condition. The gene discussed is PPARA; the disease is Hepatic steatosis.